Proteomics: Diabetes, Obesity, And Endocrine, Digestive, Kidney, Urologic, And Hematologic Diseases (R01)
National Institutes of Health · Opportunity PA-07-016
Multiple Receipt Dates - See Link to Full Announcement for details.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
About this opportunity
-Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), solicits projects that advance research to identify and quantitate protein expression patterns, post-translational modification of proteins, and protein-protein interactions on cells, tissues, organ systems relevant to diabetes, obesity, endocrine and metabolic diseases, nutritional function and diseases of the alimentary tract, exocrine pancreas, liver, kidney, bladder and prostate and normal biological processes related to the function of these systems. The development and improvement of innovative proteomic technologies is also encouraged through their application to relevant biological questions related to the pathophysiology of endocrine glands, gastrointestinal tract, liver and kidney, bladder and prostate. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-06-185, that solicits applications under the Exploratory/Developmental (R21) grant mechanism. -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Applications can be renewed by competing for additional project periods.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required) | National Institutes of Health | October 6, 2026 | — | Nonprofits |
| Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional) | National Institutes of Health | November 5, 2027 | — | Nonprofits |
| Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed) | National Institutes of Health | November 16, 2027 | — | Nonprofits |
| Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed) | National Institutes of Health | January 6, 2028 | — | Nonprofits |